Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bometase Alfa for Bleeding in Acquired Hemophilia A
NCT07789587Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Aug 2026
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Open-label, single-arm trial of bometase alfa in acquired hemophilia A (AHA), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Incidence of effective hemostasis rate at 8 hours. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
bometase alfa
03
Conditions
acquired hemophilia A (AHA)
Beyond the preview
Go deeper on NCT07789587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07789587.